Objectives: The aim of this paper is to do a review of the role of long-acting injectable antipsychotics in the treatment of schizophrenia, to describe their advantages and disadvantages over oral forms of antipsychotics, to show their importance in the problem of nonadherence in schizophrenia treatment, and to address polytherapy in schizophrenia. The expected contribution of this work is in the care and support of patients with schizophrenia and similar disorders, which pharmacists encounter on a daily basis. Materials and Methods: Relevant scientific and professional literature, psychiatric diagnostic manuals, contemporary and currently relevant therapeutic guidelines, publications of professional institutions, drug database of the Agency for Medicinal Products and Medical Devices, and other available sources were searched. Database search keywords include the following terms: antipsychotics, long-term antipsychotics, nonadherence, polytherapy, schizophrenia. Results: Although advances in the treatment of schizophrenia have significantly reduced the burden of disease, poor adherence is one of the main obstacles to achieving the set therapeutic goals, and continuity in the treatment of schizophrenia is crucial. Adherence in schizophrenia is affected by several factors (insight, cognitive impairment, polytherapy, side effects, and many others). Long-acting injectable antipsychotics for intramuscular use have been developed with the primary goal of acting on poor adherence. Numerous studies have shown certain advantages of long-acting antipsychotics compared to oral formulations: better adherence, reduced risk of recidive, reduced risk of rehospitalization, and consequently lower treatment costs. Conclusion: Long-acting injectable antipsychotics are still prescribed to a small extent for a variety of reasons. Considering their proven advantages, there is potential for larger use.